Monte Rosa Therapeutics, Inc. (GLUE)
14.31
+0.37
(+2.65%)
USD |
NASDAQ |
Sep 01, 16:00
14.31
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Cash from Investing (Quarterly) : -28.86M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -28.86M |
| March 31, 2026 | -261.00M |
| December 31, 2025 | -65.07M |
| September 30, 2025 | 38.14M |
| June 30, 2025 | 25.32M |
| March 31, 2025 | -100.23M |
| December 31, 2024 | -30.90M |
| September 30, 2024 | 37.75M |
| June 30, 2024 | -61.16M |
| March 31, 2024 | 9.853M |
| December 31, 2023 | 14.30M |
| September 30, 2023 | 35.63M |
| Date | Value |
|---|---|
| June 30, 2023 | 18.55M |
| March 31, 2023 | 20.33M |
| December 31, 2022 | -53.94M |
| September 30, 2022 | 29.49M |
| June 30, 2022 | -14.25M |
| March 31, 2022 | -180.52M |
| December 31, 2021 | -3.047M |
| September 30, 2021 | -1.688M |
| June 30, 2021 | -2.701M |
| March 31, 2021 | -2.217M |
| December 31, 2020 | -1.186M |
| September 30, 2020 | -0.93M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Nurix Therapeutics, Inc. | 93.00M |
| Gilead Sciences, Inc. | -10.35B |
| Ironwood Pharmaceuticals, Inc. | 0.00 |
| Capricor Therapeutics, Inc. | -48.76M |
| Cue Biopharma, Inc. | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.11M |
| Cash from Financing (Quarterly) | 3.211M |
| Free Cash Flow | -32.08M |
| Free Cash Flow Per Share (Quarterly) | -0.4813 |
| Free Cash Flow to Equity (Quarterly) | -47.76M |
| Free Cash Flow to Firm (Quarterly) | -48.84M |
| Free Cash Flow Yield | -2.57% |